At a Glance
| Allylescaline | 1cP-MiPLA | |
|---|---|---|
| Class | Psychedelic | Psychedelic |
| Common Dose (oral) | 30–40 mg | 150–200 µg |
| Total Duration | 0.8–4 hrs | 2.1–4.2 hrs |
| Routes | oral | oral |
| Effects | 42 documented | 70 documented |
Allylescaline, a Psychedelic, and 1cP-MiPLA, a Psychedelic, are frequently compared by users looking to understand their relative effects, dosage profiles, and safety considerations. Both are classified as Psychedelics, meaning they share a common pharmacological foundation. They share 36 documented effects in common, with 6 effects unique to Allylescaline and 34 unique to 1cP-MiPLA. This side-by-side comparison covers dosage, duration, subjective effects, and safety to help you make informed decisions.
| Allylescaline | 1cP-MiPLA | |
|---|---|---|
| Class | Psychedelic | Psychedelic |
| Common Dose (oral) | 30–40 mg | 150–200 µg |
| Total Duration | 0.8–4 hrs | 2.1–4.2 hrs |
| Routes | oral | oral |
| Effects | 42 documented | 70 documented |
| Interaction |
| Low Risk & Synergy |
| Level | Allylescaline | 1cP-MiPLA |
|---|---|---|
| Threshold | 15 mg | 50 µg |
| Light | 20–30 mg | 100–150 µg |
| Common | 30–40 mg | 150–200 µg |
| Strong | 40–60 mg | 200–250 µg |
| Heavy | 60 mg | 300 µg |
Allylescaline
1cP-MiPLA
Cross-tolerance exists; effects compound
No dangerous interactions recorded.
No dangerous interactions recorded.